Catabasis Pharmaceuticals Inc., of Cambridge, Mass., added Kenneth M. Bate to its board.

Cell Therapeutics Inc., of Seattle, added Karen Ignagni to its board.

Chelsea Therapeutics International Ltd., of Charlotte, N.C. named Keith W. Schmidt chief commercial officer.

Cleave Biosciences Inc., of San Francisco, added Lewis Shuster to its board and appointed Alessandra Cesano chief medical officer.

Enanta Pharmaceuticals Inc., of Watertown, Mass., appointed Timothy D. Ocain senior vice, new product strategy and development.

Immunogen Inc., of Waltham, Mass., named Eric Guempel vice president of product strategy and program management.

Isis Pharmaceuticals Inc., of Carlsbad, Calif., added Joseph Loscalzo to its board.

Nicox SA, of Sophia Antipolis, France, named Evelyne Nguyen chief financial officer.

Novo Nordisk A/S, of Bagsvaerd, Denmark, named Eddie Williams senior vice president of biopharmaceuticals.

Ovascience Inc., of Cambridge, Mass., appointed Jamie Grifo to its clinical advisory board.

Regulus Therapeutics Inc., of La Jolla, Calif., appointed David Szekeres chief business officer and general counsel.

Sernova Corp., of London, Ontario, appointed Cathy Steiner chief financial officer.

Sorrento Therapeutics Inc., of San Diego, added Daniel Levitt to its board.

Stem Cell Therapeutics Corp., of Toronto, named Dalvin R. Stiller chairman of its board.

Syndax Pharmaceuticals Inc., of Waltham, Mass., appointed George W. Sledge Jr. and Richard P. Shea to its board, and additionally named Shea chairman of the audit committee.

Synthetic Biologics Inc., of Rockville, Md., appointed Joseph Sliman senior vice president, clinical and regulatory affairs.

Tetraphase Pharmaceuticals Inc., of Watertown, Mass, named Craig Thompson chief operating officer.